{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:39:59Z","timestamp":1790203199606,"version":"4.1.0"},"reference-count":97,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/crd.0b013e3181ce1521","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T10:48:02Z","timestamp":1276166882000},"page":"204-212","source":"Crossref","is-referenced-by-count":75,"title":["Use of Nonsteroidal Anti-Inflammatory Drugs in Patients With Cardiovascular Disease"],"prefix":"10.1097","volume":"18","author":[{"given":"Muhammad","family":"Amer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriani R.","family":"Bead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 56","key":"R1-6-20210203","first-page":"18","article-title":"Epidemiology of NSAID induced gastrointestinal complications.","volume":"26","author":"Singh","year":"1999","journal-title":"J Rheumatol"},{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jama.282.13.1254","article-title":"The relationship between cyclooxygenase-2 expression and colorectal cancer.","volume":"282","author":"Sheehan","year":"1999","journal-title":"JAMA"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(86)92940-5","article-title":"Rising frequency of ulcer perforation in elderly people in the United Kingdom.","volume":"1","author":"Walt","year":"1986","journal-title":"Lancet"},{"key":"R4-6-20210203","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1163\/156856005774415565","article-title":"The use of NSAIDs in rheumatic disorders 2005: a global perspective.","volume":"13","author":"Kean","year":"2005","journal-title":"Inflammopharmacology"},{"key":"R5-6-20210203","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs.","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors.","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bmj.331.7528.1310","article-title":"Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.","volume":"331","author":"Hippisley-Cox","year":"2005","journal-title":"BMJ"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/archinte.162.19.2204","article-title":"Frequency of analgesic use and risk of hypertension in younger women.","volume":"162","author":"Curhan","year":"2002","journal-title":"Arch Intern Med"},{"key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/CIRCULATIONAHA.105.595793","article-title":"Non-steroidal anti-inflammatory drugs, acetaminophen, and the risk of cardiovascular events.","volume":"113","author":"Chan","year":"2006","journal-title":"Circulation"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2005.01.045","article-title":"Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.","volume":"45","author":"Capone","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R14-6-20210203","first-page":"23","article-title":"Selective cyclooxygenase inhibition: promise for future NSAID therapy?","volume":"102","author":"Fries","year":"1996","journal-title":"Scand J Rheumatol Suppl"},{"key":"R15-6-20210203","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"R16-6-20210203","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","article-title":"Use of non-steroidal anti-inflammatory drugs.","volume":"115","author":"Antman","year":"2007","journal-title":"Circulation"},{"key":"R17-6-20210203","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/bmj.323.7316.767a","article-title":"FDA warns Merck over its promotion of rofecoxib.","volume":"233","author":"Josefson","year":"2001","journal-title":"BMJ"},{"key":"R18-6-20210203","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/bmj.329.7471.867","article-title":"Lessons from the withdrawal of rofecoxib.","volume":"329","author":"Dieppe","year":"2004","journal-title":"BMJ"},{"key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(99)12031-2","article-title":"COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease.","volume":"355","author":"Willoughby","year":"2000","journal-title":"Lancet"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(03)12841-3","article-title":"COX-3: just another COX or the solitary elusive target of paracetamol?","volume":"361","author":"Schwab","year":"2003","journal-title":"Lancet"},{"key":"R21-6-20210203","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","article-title":"Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial.","volume":"282","author":"Simon","year":"1999","journal-title":"JAMA"},{"key":"R22-6-20210203","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1052-5157(18)30351-9","article-title":"Nonsteroidal anti-inflammatory drug gastropathy.","volume":"6","author":"Laine","year":"1996","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/oxfordjournals.aje.a117469","article-title":"Nonsteroidal antiinflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons.","volume":"141","author":"Smalley","year":"1995","journal-title":"Am J Epidemiol"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7326\/0003-4819-115-10-787","article-title":"Risk for serious gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs. A meta-analysis.","volume":"115","author":"Gabriel","year":"1991","journal-title":"Ann Intern Med"},{"key":"R25-6-20210203","doi-asserted-by":"crossref","first-page":"A862","DOI":"10.1016\/S0016-5085(00)85587-0","article-title":"Risk stratification of upper gastrointestinal bleeding in cardiovascular patients on low-dose aspirin. A cohort study.","volume":"118","author":"Serrano","year":"2000","journal-title":"Gastroenterology"},{"key":"R26-6-20210203","first-page":"1153","article-title":"Gastro-duodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal anti-inflammatory drug use.","volume":"82","author":"Larkai","year":"1987","journal-title":"Am J Gastroenterol"},{"key":"R27-6-20210203","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/archinte.1995.00430130043005","article-title":"Peptic ulcer and gastrointestinal hemorrhage associated with non-steroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study.","volume":"155","author":"Lanza","year":"1995","journal-title":"Arch Intern Med"},{"key":"R28-6-20210203","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)91843-0","article-title":"Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.","volume":"343","author":"Garcia Rodriguez","year":"1994","journal-title":"Lancet"},{"key":"R29-6-20210203","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/gut.46.1.27","article-title":"","volume":"46","author":"Weil","year":"2000","journal-title":"Gut"},{"key":"R30-6-20210203","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/gut.38.3.316","article-title":"Risk assessment after acute upper gastrointestinal haemorrhage.","volume":"38","author":"Rockall","year":"1996","journal-title":"Gut"},{"key":"R31-6-20210203","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","article-title":"Observational study of upper gastrointestinal hemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.","volume":"325","author":"Mamdani","year":"2002","journal-title":"BMJ"},{"key":"R32-6-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00001648-199701000-00003","article-title":"Individual non-steroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation.","volume":"8","author":"Gutthann","year":"1997","journal-title":"Epidemiology"},{"key":"R33-6-20210203","doi-asserted-by":"crossref","first-page":"R644","DOI":"10.1186\/ar1704","article-title":"Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.","volume":"7","author":"Moore","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R34-6-20210203","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/gast.2003.50054","article-title":"Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.","volume":"124","author":"Laine","year":"2003","journal-title":"Gastroenterology"},{"key":"R35-6-20210203","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial.","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"R36-6-20210203","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"A randomized controlled trial. Celecoxib long-term arthritis safety study.","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"R37-6-20210203","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1542-3565(04)00619-6","article-title":"Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.","volume":"3","author":"Goldstein","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R38-6-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/00002018-200629020-00002","article-title":"NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options.","volume":"29","author":"Naesdal","year":"2006","journal-title":"Drug Saf"},{"key":"R39-6-20210203","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1021\/ja049607w","article-title":"Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.","volume":"126","author":"Shin","year":"2004","journal-title":"J Am Chem Soc"},{"key":"R40-6-20210203","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/rheumatology\/kei241","article-title":"Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?","volume":"45","author":"Elliott","year":"2006","journal-title":"Rheumatology"},{"key":"R41-6-20210203","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2036.2008.03905.x","article-title":"Canadian consensus guidelines on long-term non-steroidal anti-inflammatory drug therapy and the need for gastro-protection: benefits versus risks.","volume":"29","author":"Rostom","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R42-6-20210203","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/gast.2003.50008","article-title":"Protective association of aspirin\/NSAIDs and esophageal cancer: a systematic review and meta analysis.","volume":"124","author":"Corley","year":"2003","journal-title":"Gastroenterology"},{"key":"R43-6-20210203","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2407-3-28","article-title":"Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis.","volume":"3","author":"Gonzalez-Perez","year":"2003","journal-title":"BMC Cancer"},{"key":"R44-6-20210203","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/jnci\/djg106","article-title":"Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis.","volume":"95","author":"Wang","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R45-6-20210203","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.bjc.6604880","article-title":"Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis.","volume":"100","author":"Abnet","year":"2009","journal-title":"Br J Cancer"},{"key":"R46-6-20210203","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jnci\/djn484","article-title":"Non-steroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.","volume":"101","author":"Grau","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 19","key":"R47-6-20210203","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00535-008-2265-7","article-title":"NSAIDs and colorectal cancer prevention.","volume":"44","author":"Iwama","year":"2009","journal-title":"J Gastroenterology"},{"issue":"suppl 19","key":"R48-6-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00535-008-2287-1","article-title":"Long-term use of non-steroidal anti-inflammatory drugs normalizes the kinetics of gastric epithelial cells in patients with Helicobacter pylori infection via attenuation of gastric mucosal inflammation.","volume":"44","author":"Tanigawa","year":"2009","journal-title":"J Gastroenterology"},{"key":"R49-6-20210203","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding.","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"key":"R50-6-20210203","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10620-007-9903-4","article-title":"Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or co-administered with celecoxib or naproxen: a randomized, 1-week trial.","volume":"53","author":"Goldstein","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R51-6-20210203","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2000.02248.x","article-title":"Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.","volume":"95","author":"S\u00f8rensen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R52-6-20210203","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","article-title":"Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.","volume":"121","author":"Johnson","year":"1994","journal-title":"Ann Intern Med"},{"key":"R53-6-20210203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00045391-200103000-00003","article-title":"Cyclooxygenase-2-specific inhibitors and cardio-renal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.","volume":"8","author":"Whelton","year":"2001","journal-title":"Am J Ther"},{"key":"R54-6-20210203","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0002-9149(02)02661-9","article-title":"Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis.","volume":"90","author":"Whelton","year":"2002","journal-title":"Am J Cardiol"},{"key":"R55-6-20210203","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archinte.165.2.161","article-title":"The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.","volume":"165","author":"Sowers","year":"2005","journal-title":"Arch Intern Med"},{"key":"R56-6-20210203","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archinte.160.6.777","article-title":"Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under recognized public health problem.","volume":"160","author":"Page","year":"2000","journal-title":"Arch Intern Med"},{"key":"R57-6-20210203","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.158.10.1108","article-title":"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.","volume":"158","author":"Heerdink","year":"1998","journal-title":"Arch Intern Med"},{"key":"R58-6-20210203","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.EDE.0000034633.74133.C3","article-title":"Non-steroidal anti-inflammatory drugs as a trigger of clinical heart failure.","volume":"14","author":"Garc\u00eda Rodr\u00edguez","year":"2003","journal-title":"Epidemiology"},{"key":"R59-6-20210203","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJM198403013100905","article-title":"Renal syndromes associated with nonsteroidal anti-inflammatory drugs.","volume":"310","author":"Clive","year":"1984","journal-title":"N Engl J Med"},{"key":"R60-6-20210203","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM198402093100603","article-title":"Prostaglandins in severe congestive heart failure.","volume":"310","author":"Dzau","year":"1984","journal-title":"N Engl J Med"},{"key":"R61-6-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease.","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"R62-6-20210203","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.ATV.0000104005.92603.f2","article-title":"Cyclooxygenase-2 expression and inhibition in atherothrombosis.","volume":"24","author":"Cipollone","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R63-6-20210203","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1161\/01.CIR.0000014927.74465.7F","article-title":"Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.","volume":"105","author":"Burleigh","year":"2002","journal-title":"Circulation"},{"key":"R64-6-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI200113455","article-title":"Genetic and pharmacological analysis of prostanoid receptor function.","volume":"108","author":"Narumiya","year":"2001","journal-title":"J Clin Invest"},{"key":"R65-6-20210203","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1172\/JCI5116","article-title":"Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.","volume":"102","author":"Thomas","year":"1998","journal-title":"J Clin Invest"},{"key":"R66-6-20210203","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(78)91806-8","article-title":"Prostacyclin can replace heparin in hemodialysis in dogs.","volume":"2","author":"Woods","year":"1978","journal-title":"Lancet"},{"key":"R67-6-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(77)91655-5","article-title":"Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.","volume":"1","author":"Moncada","year":"1977","journal-title":"Lancet"},{"key":"R68-6-20210203","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0008-6363(02)00414-5","article-title":"Discovery of a new function of cyclooxygenase (COX)-2.","volume":"55","author":"Bolli","year":"2000","journal-title":"Cardiovasc Res"},{"key":"R69-6-20210203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jacc.2003.09.043","article-title":"Non-steroidal anti-inflammatory drugs and cardiovascular risk.","volume":"43","author":"Howard","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R70-6-20210203","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1161\/01.CIR.0000143234.51796.A9","article-title":"Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo.","volume":"110","author":"Buerkle","year":"2004","journal-title":"Circulation"},{"key":"R71-6-20210203","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/hc3301.092790","article-title":"Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.","volume":"104","author":"Hennan","year":"2001","journal-title":"Circulation"},{"key":"R72-6-20210203","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A2.","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"key":"R73-6-20210203","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2362.2004.01334.x","article-title":"Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood.","volume":"34","author":"Hernandez","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R74-6-20210203","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/01.CIR.0000051361.69808.3A","article-title":"COX-2 inhibition improves endothelial function in coronary artery disease.","volume":"107","author":"Chenevard","year":"2003","journal-title":"Circulation"},{"key":"R75-6-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0021-9150(00)00756-5","article-title":"Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits.","volume":"157","author":"Wong","year":"2001","journal-title":"Atherosclerosis"},{"key":"R76-6-20210203","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1161\/01.ATV.0000074879.19006.51","article-title":"Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.","volume":"23","author":"Tuleja","year":"2003","journal-title":"Arterioscler Throm Vasc Biol"},{"key":"R77-6-20210203","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","article-title":"Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDS. A population-based case-control study.","volume":"165","author":"Johnsen","year":"2005","journal-title":"Arch Int Med"},{"key":"R78-6-20210203","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"R79-6-20210203","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","article-title":"Risk of cardiovascular events and rofecoxib: cumulative metaanalysis.","volume":"364","author":"Juni","year":"2004","journal-title":"Lancet"},{"key":"R80-6-20210203","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"R81-6-20210203","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial.","volume":"364","author":"Farkouh","year":"2004","journal-title":"Lancet"},{"key":"R82-6-20210203","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCOUTCOMES.108.805689","article-title":"Cardiovascular risks of non-steroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.","volume":"2","author":"Ray","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R83-6-20210203","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Quan H, et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.","volume":"352","author":"Bresalier","year":"200517","journal-title":"N Engl J Med"},{"key":"R84-6-20210203","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/01.CIR.0000160005.90598.41","article-title":"The use of non-steroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association.","volume":"111","author":"Bennett","year":"2005","journal-title":"Circulation"},{"key":"R85-6-20210203","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","article-title":"Celecoxib for the prevention of colorectal adenomatous polyps.","volume":"355","author":"Arber","year":"2006","journal-title":"N Engl J Med"},{"key":"R86-6-20210203","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0091270005278202","article-title":"The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.","volume":"45","author":"Konstantinopoulos","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R87-6-20210203","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1371\/journal.pctr.0010033","article-title":"Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).","volume":"1","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"R88-6-20210203","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","article-title":"Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison.","volume":"368","author":"Cannon","year":"2006","journal-title":"Lancet"},{"key":"R89-6-20210203","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/ard.2007.076760","article-title":"Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients.","volume":"68","author":"Goodson","year":"2009","journal-title":"Ann Rheumatic Dis"},{"key":"R90-6-20210203","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/eurheartj\/ehl053","article-title":"NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland.","volume":"27","author":"Helin-Salmivaara","year":"2006","journal-title":"Eur Heart J"},{"key":"R92-6-20210203","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/009127002401102858","article-title":"Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers.","volume":"42","author":"Wilner","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R93-6-20210203","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin.","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"key":"R94-6-20210203","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","article-title":"Inhibition of clinical benefits of aspirin on first myocardial infarction by non-steroidal anti-inflammatory drugs.","volume":"108","author":"Kurth","year":"2003","journal-title":"Circulation"},{"key":"R95-6-20210203","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/ard.2006.065904","article-title":"The effect of weight reduction in obese patients diagnosed with knee osteoarthritis (OA): a systematic review and meta-analysis.","volume":"66","author":"Christensen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R96-6-20210203","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/art.1780381104","article-title":"Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology.","volume":"38","author":"Hochberg","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R97-6-20210203","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00402-007-0447-z","article-title":"What is the evidence for visco supplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature.","volume":"128","author":"Van den Bekerom","year":"2008","journal-title":"Arch Orthop Trauma Surg"},{"key":"R98-6-20210203","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.joca.2004.11.010","article-title":"Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity.","volume":"13","author":"Goldberg","year":"2005","journal-title":"Osteoarthritis Cartilage"},{"key":"R99-6-20210203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amjcard.2006.07.069","article-title":"Risk of cardiovascular events in patients receiving celecoxib: a metaanalysis of randomized clinical trials.","volume":"99","author":"White","year":"2007","journal-title":"Am J Cardiol"},{"key":"R100-6-20210203","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ahj.2008.12.014","article-title":"Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.","volume":"157","author":"Becker","year":"2009","journal-title":"Am Heart J"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045415-201007000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T05:56:51Z","timestamp":1618034211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201007000-00006"}},"subtitle":["A Cautionary Tale"],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e3181ce1521","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}